Clearmind Medicine Announces Successful Completion of Treatment and Follow-up for 18 Participants in its Ongoing Phase I/IIa Clinical Trial of CMND-100 for Alcohol Use Disorder
MWN-AI** Summary
Clearmind Medicine Inc. (Nasdaq: CMND), a biotech company specializing in non-hallucinogenic therapeutics, announced the successful completion of treatment and follow-up for 18 participants in its ongoing Phase I/IIa clinical trial of CMND-100, aimed at treating Alcohol Use Disorder (AUD). This trial, which is FDA-approved, evaluates the safety, tolerability, pharmacokinetics, and preliminary efficacy of CMND-100, a proprietary MEAI-based oral drug candidate, in patients with moderate to severe AUD.
The announcement comes as the company successfully treated four additional participants at its clinical site in Tel Aviv, highlighting the operational strength of its Israeli clinical centers. Dr. Adi Zuloff-Shani, Clearmind’s CEO, expressed optimism regarding these developments, stating that the steady progress across trial sites underscores the promising safety and tolerability profile of CMND-100, bringing the company closer to potentially offering an innovative solution for AUD.
The trial involves prestigious institutions such as Yale University and Johns Hopkins University, indicating a robust research framework. Clearmind is distinct in its focus on neuroplastogen-derived therapeutics, striving to address under-served health issues with its unique compounds.
Currently, Clearmind’s intellectual property portfolio includes 19 patent families and 31 granted patents, and the company plans to pursue more patents while exploring additional intellectual property acquisition opportunities. This strategic positioning aims to enhance the development of novel therapies. The stock is actively traded on Nasdaq under the symbol "CMND."
Investors should be cautious as this announcement includes forward-looking statements, highlighting the inherent uncertainties and risks associated with clinical trials and drug development processes. For more information, Clearmind provides resources on its website.
MWN-AI** Analysis
Clearmind Medicine Inc. (Nasdaq: CMND) has made significant strides in its Phase I/IIa clinical trial of CMND-100, a novel therapy for Alcohol Use Disorder (AUD). The successful treatment completion for 18 participants, along with four additional patients at its Israeli site, showcases the company's operational efficiency and commitment to addressing an often neglected health crisis. This progress is particularly notable given the trial's involvement with prestigious institutions like Yale University and Johns Hopkins, underscoring the credibility of Clearmind's research and development endeavors.
Investors should take heed of the implications stemming from these latest updates. The positive results may indeed enhance CMND's stock performance as the market typically responds favorably to advancements in clinical trials, particularly in the biotech sector. Furthermore, the non-hallucinogenic nature of CMND-100 positions it as a potentially groundbreaking solution in a market hungry for novel treatments for AUD. Given the mounting concerns surrounding alcohol addiction and the limitations of current therapies, Clearmind's innovation could meet a significant unmet need, thereby attracting interest from both healthcare providers and investors alike.
However, while the current momentum is encouraging, potential investors should remain cognizant of the inherent risks associated with clinical trials, including regulatory hurdles and market competition. Clearmind's reliance on thorough and positive results from ongoing studies will be essential for maintaining investor confidence and achieving commercial viability.
Setting a watchful eye on subsequent phases of the trial, as well as broader industry trends surrounding neuroplastogens and clinical outcomes in addiction treatment, will be crucial for stakeholders. A cautious but optimistic approach is advisable, holding positions while monitoring developments closely to capture potential valuation increases as Clearmind advances in its mission to innovate alcohol addiction therapies.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
Company completed treatment in four additional participate at its Israel clinical site
Vancouver, Canada, March 30, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on the discovery and development of novel, non-hallucinogenic, second generation, neuroplastogen-derived therapeutics to solve major under-treated health problems, today announced the successful completion of treatment and follow-up of 18 participants in its ongoing FDA-approved Phase I/IIa clinical trial evaluating CMND-100, the Company’s proprietary non-hallucinogenic MEAI-based oral drug candidate, for the treatment of Alcohol Use Disorder (AUD).
This milestone reflects continued positive progress and strong momentum in the multinational, multicenter study, which is designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of CMND-100 in patients with moderate to severe AUD.
The Company also wishes to announce that four additional participants have been successfully treated at the clinical center in Tel Aviv, further expanding enrollment and demonstrating the operational strength of the Israeli sites in the trial.
“We are very encouraged by the successful completion of treatment and follow-up for these 18 participants, alongside the rapid addition of four more patients at our Tel Aviv center,” said Dr. Adi Zuloff-Shani, Chief Executive Officer of Clearmind Medicine. “This steady progress across our sites underscores the favorable safety and tolerability profile of CMND-100 and brings us closer to potentially delivering a much-needed innovative therapy for Alcohol Use Disorder.”
The Phase I/IIa clinical trial is being conducted at leading institutions, including Yale University, Johns Hopkins University, Tel Aviv Sourasky Medical Center, and Hadassah Medical Center.
About Clearmind Medicine Inc.
Clearmind is a clinical-stage neuroplastogens pharmaceutical biotech company focused on the discovery and development of non-hallucinogenic, second generation, neuroplastogen-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods, or supplements.
The Company’s intellectual portfolio currently consists of nineteen patent families, including 31 granted patents. The Company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.
Shares of Clearmind are listed for trading on Nasdaq under the symbol "CMND."
For further information, visit: https://www.clearmindmedicine.com or contact:
Investor Relations
invest@clearmindmedicine.com
www.Clearmindmedicine.com
Forward-Looking Statements:
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act and other securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. For example, the Company is using forward-looking statements when it discusses the timing and progress of its clinical trials and potentially delivering a much-needed innovative therapy for Alcohol Use Disorder. Forward-looking statements are not historical facts, and are based upon management’s current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management’s expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company’s reports filed from time to time with the Securities and Exchange Commission (“SEC”), including, but not limited to, the risks detailed in the Company’s annual report on Form 20-F for the fiscal year ended October 31, 2025 and subsequent filings with the SEC. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Clearmind is not responsible for the contents of third-party websites.
FAQ**
What specific data or results regarding CMND-100's efficacy have been observed in the participants treated in the Phase I/IIa clinical trial by Clearmind Medicine Inc. CMND?
How does Clearmind Medicine Inc. CMND plan to expand its clinical trials beyond the current sites, and what additional participants are expected to be enrolled?
Can Clearmind Medicine Inc. CMND provide more details on the safety and tolerability profile observed during the trial, based on the experiences of the initial participants?
What are the next steps for Clearmind Medicine Inc. CMND following the successful treatment of additional participants in Israel, and how does this impact their timeline for potential commercialization?
**MWN-AI FAQ is based on asking OpenAI questions about Clearmind Medicine Inc. (NASDAQ: CMND).
NASDAQ: CMND
CMND Trading
41.04% G/L:
$3.53 Last:
41,970,858 Volume:
$3.49 Open:
